Hyatt Regency Newport Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2016
Here are the related meetings in 2021:
Harnessing the Microbiome for Disease Prevention and Therapy (EK12)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Gut Microbiota, Metabolic Disorders and Beyond (D4)
Organizer(s) Rémy G. Burcelin, Sven Pettersson and Tak W. Mak
April 17—21, 2016
Hyatt Regency Newport • Newport, RI USA
Discounted Abstract Deadline: Dec 17, 2015
Abstract Deadline: Jan 20, 2016
Scholarship Deadline: Dec 17, 2015
Discounted Registration Deadline: Feb 17, 2016
Sponsored by Curemark LLC, Nestlé Institute of Health Sciences and Novartis Institutes for BioMedical Research
Summary of Meeting:
The hologenome theory of evolution proposes that natural selection acts not on the individual organism but rather on the “holobiont,” which consists of the organism together with microbiome (its genes and metabolites). When a holobiont is challenged by dramatic changes, such as altered diet or reduced physical activity, it employs adaptive mechanisms in the form of reshuffling its microbiome (resident microbial communities), but the underlying mechanisms of this molecular crosstalk remain to be determined. Effective study of the holobiont requires a systems biology approach: remove one component of the holobiont to study it in reductionist style and other parts also altered will be overlooked. Decades of reductionist research aimed at understanding the mechanisms responsible for the current dramatic epidemic of man-made metabolic diseases have not considered the holobiont perspective and have consequently missed the adaptation strategies of the microbiome but have set the stage to explore the inchoate holobiont perspective. Application of a systems biology approach to decipher molecular mechanisms underlying man-made metabolic diseases presents a unique opportunity to develop novel therapies that sustain health in a personalized manner. This meeting will discuss how the gut microbiome and its metabolites influence major molecular and physiological mechanisms responsible for man-made metabolic diseases. It will therefore incorporate investigators from diverse areas such as medicine, immunology, neurobiology, endocrinology, physiology, psychiatry, systems biology and microbiology. In addition, the nutritional, surgical and pharmacological aspects of innovative therapeutic strategies will be discussed in dialogue with scientists from pharmaceutical/nutritional companies. The gut microbiome is a neuroendocrine and antigenic organ whose rediscovery is necessary for our understanding of man-made metabolic diseases in the context of the holobiont.
View Scholarships/Awards
The hologenome theory of evolution proposes that natural selection acts not on the individual organism but rather on the “holobiont,” which consists of the organism together with microbiome (its genes and metabolites). When a holobiont is challenged by dramatic changes, such as altered diet or reduced physical activity, it employs adaptive mechanisms in the form of reshuffling its microbiome (resident microbial communities), but the underlying mechanisms of this molecular crosstalk remain to be determined. Effective study of the holobiont requires a systems biology approach: remove one component of the holobiont to study it in reductionist style and other parts also altered will be overlooked. Decades of reductionist research aimed at understanding the mechanisms responsible for the current dramatic epidemic of man-made metabolic diseases have not considered the holobiont perspective and have consequently missed the adaptation strategies of the microbiome but have set the stage to explore the inchoate holobiont perspective. Application of a systems biology approach to decipher molecular mechanisms underlying man-made metabolic diseases presents a unique opportunity to develop novel therapies that sustain health in a personalized manner. This meeting will discuss how the gut microbiome and its metabolites influence major molecular and physiological mechanisms responsible for man-made metabolic diseases. It will therefore incorporate investigators from diverse areas such as medicine, immunology, neurobiology, endocrinology, physiology, psychiatry, systems biology and microbiology. In addition, the nutritional, surgical and pharmacological aspects of innovative therapeutic strategies will be discussed in dialogue with scientists from pharmaceutical/nutritional companies. The gut microbiome is a neuroendocrine and antigenic organ whose rediscovery is necessary for our understanding of man-made metabolic diseases in the context of the holobiont.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, April 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 21 with a closing plenary session and keynote address from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 22 in order to fully experience the meeting.
SUNDAY, APRIL 17
MONDAY, APRIL 18
TUESDAY, APRIL 19
WEDNESDAY, APRIL 20
THURSDAY, APRIL 21
FRIDAY, APRIL 22
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, April 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 21 with a closing plenary session and keynote address from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 22 in order to fully experience the meeting.
SUNDAY, APRIL 17
16:00—20:00
Arrival and Registration
Ballroom Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
Ballroom Foyer
07:30—08:30
Breakfast
Rose Island
08:30—09:30
Welcome and Keynote Address
Grand Ballroom
*
Sven Pettersson,
Nanyang Technological University, Singapore
Jeremy K. Nicholson,
Imperial College London, UK
Towards Personalized Medicine and Microbiome Regulation
Towards Personalized Medicine and Microbiome Regulation
09:30—12:00
Gut Microbiota Biology, Microbiome and Evolution throughout Metabolic Diseases
Grand Ballroom
*
Rémy G. Burcelin,
Institute of Molecular Medicine, France
*
Matteo Serino,
INSERM, France
Francois-Pierre Martin,
Nestlé Institute of Health Sciences, Switzerland
The Human GI Tract and its Microbiome: From Associations to Interactions
The Human GI Tract and its Microbiome: From Associations to Interactions
Stephan C. Schuster,
Nanyang Technological University, Singapore
Holobiont Concept and Tissue Compartment and Microbiome
Holobiont Concept and Tissue Compartment and Microbiome
Michael A. Fischbach,
Stanford University, USA
Small Molecules from the Human Microbiota
Small Molecules from the Human Microbiota
Filipe De Vadder,
University of Gothenburg, Sweden
Short Talk: The Gut Microbiota Induces Adult Neurogenesis in the Enteric Nervous System
Short Talk: The Gut Microbiota Induces Adult Neurogenesis in the Enteric Nervous System
Carmen A.K. Emborski,
Texas Tech University, USA
Short Talk: Evidence for Metabolic Inheritance via Microbial Transfer
Short Talk: Evidence for Metabolic Inheritance via Microbial Transfer
10:10—10:30
Coffee Break
Ballroom Foyer
12:00—14:30
On Own for Lunch
12:00—13:00
Poster Setup
Brenton Hall
13:00—22:00
Poster Viewing
Brenton Hall
14:30—16:30
Workshop 1: Microbiota-Related Biomarkers
Grand Ballroom
*
Jeremy K. Nicholson,
Imperial College London, UK
*
Sven Pettersson,
Nanyang Technological University, Singapore
Shirong Liu,
Brigham and Women's Hospital/Harvard Medical School, USA
Fecal microRNAs Shape Gut Microbiota
Fecal microRNAs Shape Gut Microbiota
Bailey Peck,
University of Michigan, USA
Gut Microbiota Responsive miR-375 Regulates Intestinal Epithelial Stem Cell Proliferation
Gut Microbiota Responsive miR-375 Regulates Intestinal Epithelial Stem Cell Proliferation
Cheng-Yuan Kao,
National Health Research Institutes, Taiwan
A Multi-Omics Study Reveals Insights in Gut Microbiota and Mucosal Immunity in Obesity Resistance
A Multi-Omics Study Reveals Insights in Gut Microbiota and Mucosal Immunity in Obesity Resistance
Sangeeta Khare,
National Center for Toxicological Research-US-FDA, USA
Evaluation of the Silver Nanoparticles on Gut Virus/Phages and its Outcome on the Expression of Genes Involved in the Innate Antiviral Immune Response in Gut
Evaluation of the Silver Nanoparticles on Gut Virus/Phages and its Outcome on the Expression of Genes Involved in the Innate Antiviral Immune Response in Gut
Ara Koh,
Gothenburg University, Sweden
Microbiota-Mediated Intestinal Cell Fate Decision Occurs Primarily in Jejunum – Use of Intestinal Organoids
Microbiota-Mediated Intestinal Cell Fate Decision Occurs Primarily in Jejunum – Use of Intestinal Organoids
Kimberly A. Krautkramer,
University of Gothenburg, Sweden
Gut Microbiota Affect Host Epigenetic State
Gut Microbiota Affect Host Epigenetic State
16:30—17:00
Coffee Available
Ballroom Foyer
17:00—19:00
Tissue Communication
Grand Ballroom
*
Michael A. Fischbach,
Stanford University, USA
*
Francois-Pierre Martin,
Nestlé Institute of Health Sciences, Switzerland
James Versalovic,
Texas Children's Hospital, USA
Gut Microbiome and Amino Acid Metabolism
Gut Microbiome and Amino Acid Metabolism
Ruth E. Ley,
Max Planck Institute for Developmental Biology, Germany
Host Genetic Regulation of the Microbiome with Consequences for Phenotype
Host Genetic Regulation of the Microbiome with Consequences for Phenotype
Kairui Mao,
NIAID, National Institutes of Health, USA
Short Talk: Direct Visualization of Signaling Crosstalk Between the Microbiota and Immune System
Short Talk: Direct Visualization of Signaling Crosstalk Between the Microbiota and Immune System
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Brenton Hall
19:30—22:00
Poster Session 1
Brenton Hall
07:30—08:30
Breakfast
Rose Island
08:00—08:30
Poster Setup
Brenton Hall
08:30—17:00
Poster Viewing
Brenton Hall
08:30—11:45
Early Development - Maternal Life, Brain and Metabolic Development
Grand Ballroom
*
Ruth E. Ley,
Max Planck Institute for Developmental Biology, Germany
*
Stephan C. Schuster,
Nanyang Technological University, Singapore
Kjersti M. Aagaard,
Baylor College of Medicine and Texas Children’s Hospital, USA
Unexpected Beginnings: Role of Pregnancy and Parturition in Establishing our Microbiome
Unexpected Beginnings: Role of Pregnancy and Parturition in Establishing our Microbiome
Bernard Thorens,
University of Lausanne, Switzerland
Glucose Signaling: Is There a Room for Microbiota?
Glucose Signaling: Is There a Room for Microbiota?
Berengere Coupe,
Vaiomer, France
Tissue Microbiota-Derived Therapeutic Strategies in Metabolic Disease
Tissue Microbiota-Derived Therapeutic Strategies in Metabolic Disease
Martin J. Blaser,
New York University School of Medicine, USA
Early Life Microbiota Development affects Long-Term Metabolic and Immunologic Consequences
Early Life Microbiota Development affects Long-Term Metabolic and Immunologic Consequences
Hans Rudolf Berthoud,
Pennington Biomedical Research Center, USA
Short Talk: Maternal Transplantation of High-Fat Diet/Obesity Shaped Gut Microbiota Affects Offspring Cognitive and Emotional Behavior in a Sex-Specific Manner
Short Talk: Maternal Transplantation of High-Fat Diet/Obesity Shaped Gut Microbiota Affects Offspring Cognitive and Emotional Behavior in a Sex-Specific Manner
Taylor Kristina Soderborg,
University of Colorado Denver, USA
Short Talk: Maternal Obesity and Gestational Diabetes Alters 2 Week Human Infant Microbiome and Drives Metabolic Processes in Germ-Free Mice
Short Talk: Maternal Obesity and Gestational Diabetes Alters 2 Week Human Infant Microbiome and Drives Metabolic Processes in Germ-Free Mice
09:50—10:10
Coffee Break
Ballroom Foyer
11:45—12:30
Lunch
Brenton Hall
12:00—14:30
Poster Session 2
Brenton Hall
14:30—16:30
Workshop 2: Novel Mechanisms of Microbiota Regulated Metabolic Functions
Grand Ballroom
*
Martin J. Blaser,
New York University School of Medicine, USA
*
Rémy G. Burcelin,
Institute of Molecular Medicine, France
Paola Tognini,
University of California, Irvine, USA
Intestinal Microbiota Influences Circadian Clock Function and Homeostasis in the Liver upon Food Stress
Intestinal Microbiota Influences Circadian Clock Function and Homeostasis in the Liver upon Food Stress
Suzanne Devkota,
Cedars-Sinai Medical Center, USA
Feast or Famine: Sustained Reshaping of the Gut Microbiota in Response to Fasting and Re-Feeding
Feast or Famine: Sustained Reshaping of the Gut Microbiota in Response to Fasting and Re-Feeding
Mukul Prasad,
National University of Singapore, Singapore
T-Cell Specific Signaling Molecule Themis in Development of Metabolic Disorder
T-Cell Specific Signaling Molecule Themis in Development of Metabolic Disorder
Shiho Fujisaka,
Joslin Diabetes Center and Harvard Medical School, USA
Antibiotic Effects on Gut Microbiota, Insulin Signaling and Bile Acid Metabolism is Dependent on Host Genetic Background
Antibiotic Effects on Gut Microbiota, Insulin Signaling and Bile Acid Metabolism is Dependent on Host Genetic Background
Edina Hot,
European Institute of Oncology, Italy
Effects of Concurrent Administration of OCA and MCD Diet on NASH and Gut Vascular Barrier Permeability in Mice
Effects of Concurrent Administration of OCA and MCD Diet on NASH and Gut Vascular Barrier Permeability in Mice
Sean Davies,
Vanderbilt University, USA
Inhibiting Obesity with Engineered Therapeutic Bacteria
Inhibiting Obesity with Engineered Therapeutic Bacteria
Hasinika Gamage,
Macquarie University, Australia
Fibre Products Derived from Sugarcane, Wheat Dextrin and Psyllium Husk Influence the Gut Microbiota in vitro
Fibre Products Derived from Sugarcane, Wheat Dextrin and Psyllium Husk Influence the Gut Microbiota in vitro
Diana E. Roopchand,
Rutgers University, USA
Gut Microbiota: A Missing Link for the Bioactivity of Dietary Polyphenols
Gut Microbiota: A Missing Link for the Bioactivity of Dietary Polyphenols
16:30—17:00
Coffee Available
Ballroom Foyer
17:00—19:15
Therapeutic Strategies
Grand Ballroom
*
Filipe De Vadder,
University of Gothenburg, Sweden
*
Charles R. Mackay,
Monash University, Australia
Max Nieuwdorp,
University of Amsterdam, Netherlands
Fecal Transplantation – Ongoing Trials Pros and Cons
Fecal Transplantation – Ongoing Trials Pros and Cons
Filipe J. Gomes Cabreiro,
Imperial College London, UK
Host-Microbial Metabolic Complementation Modulates the Effects of Fluoropyrimidines in C. elegans Survival and Longevity
Host-Microbial Metabolic Complementation Modulates the Effects of Fluoropyrimidines in C. elegans Survival and Longevity
Elaine Holmes,
Imperial College London, UK
Bariatric Surgery and Microbial Metabolites
Bariatric Surgery and Microbial Metabolites
Hao Wu,
University of Gothenburg, Sweden
Short Talk: Insights into Metformin-Microbiota Interactions in Treatment of T2D: A Placebo-Controlled, Double-Blinded, and Treatment-Naïve Study
Short Talk: Insights into Metformin-Microbiota Interactions in Treatment of T2D: A Placebo-Controlled, Double-Blinded, and Treatment-Naïve Study
Emma D'Agostino,
University of North Carolina at Chapel Hill, USA
Short Talk: The Human GI Microbial GUSome, a Constellation of Drug Targets in the Microbiome
Short Talk: The Human GI Microbial GUSome, a Constellation of Drug Targets in the Microbiome
19:15
On Own for Dinner
07:30—08:30
Breakfast
Rose Island
08:30—11:45
Small Intestine Liver Function, Bile Acids, Therapy
Grand Ballroom
*
Max Nieuwdorp,
University of Amsterdam, Netherlands
*
Elaine Holmes,
Imperial College London, UK
Lora V. Hooper,
University of Texas Southwestern Medical Center, USA
Circadian Regulation of Intestinal Host-Microbe Interactions
Circadian Regulation of Intestinal Host-Microbe Interactions
Lotta Stenman,
DuPont Nutrition and Health, Finland
Therapeutic Efficacy and Mechanisms of Probiotics and Prebiotics in Metabolic Disease
Therapeutic Efficacy and Mechanisms of Probiotics and Prebiotics in Metabolic Disease
Fredrik Bäckhed,
University of Gothenburg, Sweden
Gut Microbial Regulation of Bile Acids and FXR Signaling in Metabolic Disease
Gut Microbial Regulation of Bile Acids and FXR Signaling in Metabolic Disease
Paolo Sassone-Corsi,
University of California, Irvine, USA
Molecular Mechanisms Linking the Gut Microbiota to the Circadian Clock
Molecular Mechanisms Linking the Gut Microbiota to the Circadian Clock
Kristien Bouter†,
University of Amsterdam, Academic Medical Center, Netherlands
Short Talk: Oral Butyrate Treatment has Differential Effects on Insulin Sensitivity in Healthy Versus Metabolic Syndrome Subjects
Short Talk: Oral Butyrate Treatment has Differential Effects on Insulin Sensitivity in Healthy Versus Metabolic Syndrome Subjects
Youngji (Helen) Cho,
Harvard University, USA
Short Talk: Bile Acid Metabolism, Gut Microbiota, and Pulmonary Responses to Ozone
Short Talk: Bile Acid Metabolism, Gut Microbiota, and Pulmonary Responses to Ozone
09:50—10:10
Coffee Break
Ballroom Foyer
11:45—17:00
On Own for Lunch
11:45—13:00
Poster Setup
Brenton Hall
13:00—22:00
Poster Viewing
Brenton Hall
16:30—17:00
Coffee Available
Ballroom Foyer
17:00—19:15
Immunity and Metabolism
Grand Ballroom
*
Filipe J. Gomes Cabreiro,
Imperial College London, UK
*
Tak W. Mak,
Campbell Family Institute for Breast Cancer, Canada
Low Grade Inflammation and Impact on Metabolic Circuits
Low Grade Inflammation and Impact on Metabolic Circuits
Rémy G. Burcelin,
Institute of Molecular Medicine, France
Gut Microbiota-impaired Intestinal Immune Defense and Diabetes
Gut Microbiota-impaired Intestinal Immune Defense and Diabetes
Maayan Levy,
University of Pennsylvania, USA
Short Talk: Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling
Short Talk: Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling
Chrysothemis Brown,
Sloan Kettering Institute, USA
Short Talk: Retinoic Acid: A Metabolic Checkpoint during CD4+ T Cell Differentiation
Short Talk: Retinoic Acid: A Metabolic Checkpoint during CD4+ T Cell Differentiation
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Brenton Hall
19:30—22:00
Poster Session 3
Brenton Hall
07:30—08:30
Breakfast
Rose Island
08:30—11:45
Fat Muscle Function, Therapeutic Aging, Immunity
Grand Ballroom
*
Lora V. Hooper,
University of Texas Southwestern Medical Center, USA
*
Paolo Sassone-Corsi,
University of California, Irvine, USA
Diane Mathis,
Harvard Medical School, USA
Diabetes-Protective HLA/MHC Alleles Operate via the Microbiota
Diabetes-Protective HLA/MHC Alleles Operate via the Microbiota
Jorge L. Ruas,
Karolinska Institutet, Sweden
Skeletal Muscle Kynurenine Metabolism in Metabolic and Psychiatric Diseases
Skeletal Muscle Kynurenine Metabolism in Metabolic and Psychiatric Diseases
Charles R. Mackay,
Monash University, Australia
Diet, Bacterial Metabolites and "Western Lifestyle" Inflammatory Diseases
Diet, Bacterial Metabolites and "Western Lifestyle" Inflammatory Diseases
Jose Manuel Manuel Fernández-Real,
Hospital of Girona, Spain
Iron, Microbiota and NASH
Iron, Microbiota and NASH
Janelle S. Ayres,
The Salk Institute for Biological Studies, USA
Short Talk: Muscle Wasting Protection Mediated by Microbiome E. coli Involves Inflammasome and IGF-1 Signaling
Short Talk: Muscle Wasting Protection Mediated by Microbiome E. coli Involves Inflammasome and IGF-1 Signaling
John R. Kirby,
Medical College of Wisconsin, USA
Short Talk: Risperidone Treatment Alters Bacteria and Phage Populations in the Gut to Suppress Metabolic Rates Leading to Weight Gain
Short Talk: Risperidone Treatment Alters Bacteria and Phage Populations in the Gut to Suppress Metabolic Rates Leading to Weight Gain
09:50—10:10
Coffee Break
Ballroom Foyer
11:45—17:00
On Own for Lunch
16:30—17:00
Coffee Available
Ballroom Foyer
17:00—18:00
Gut Immunity, Barrier Function and Effects on Metabolism
Grand Ballroom
*
Diane Mathis,
Harvard Medical School, USA
*
Tak W. Mak,
Campbell Family Institute for Breast Cancer, Canada
Dan R. Littman,
HHMI/New York University School of Medicine, USA
The Gut Microbiota to Immune System Molecular Crosstalk
The Gut Microbiota to Immune System Molecular Crosstalk
Sven Pettersson,
Nanyang Technological University, Singapore
Bidirectional Communication Pathways between the Gut Microbiome and its Host Influencing Host Physiology in an Age-Dependent Manner
Bidirectional Communication Pathways between the Gut Microbiome and its Host Influencing Host Physiology in an Age-Dependent Manner
18:00—18:45
Closing Keynote Address
Grand Ballroom
*
Dan R. Littman,
HHMI/New York University School of Medicine, USA
Lewis C. Cantley,
Weill Cornell Medicine, USA
Gut Microbiota Biology, Microbiome and Evolution throughout Metabolic Diseases
Gut Microbiota Biology, Microbiome and Evolution throughout Metabolic Diseases
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Grand Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Brenton Hall
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
Brenton Hall
Departure
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
